Cargando…

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma

BACKGROUND: Axitinib, a selective and potent tyrosine kinase inhibitor of vascular endothelial growth factor receptors, was available to patients from Canada and Australia, prior to regulatory approval of axitinib in these countries, for treatment of clear-cell metastatic renal cell carcinoma (mRCC)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Karakiewicz, Pierre I, Nott, Louise, Joshi, Abhishek, Kannourakis, George, Tarazi, Jamal, Alam, Mahmood
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove Medical Press 2016
Materias:	Clinical Trial Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4869634/ https://www.ncbi.nlm.nih.gov/pubmed/27274281 http://dx.doi.org/10.2147/OTT.S102578

Ejemplares similares

Choi criteria are superior in evaluating tumor response in patients treated with transarterial radioembolization for hepatocellular carcinoma
por: WENG, ZHIHONG, et al.
Publicado: (2013)

Comparison of Choi, RECIST and Somatostatin Receptor PET/CT Based Criteria for the Evaluation of Response and Response Prediction to PRRT
por: Zwirtz, Kevin, et al.
Publicado: (2022)

RECIST and CHOI criteria in the evaluation of tumor response in patients with metastatic colorectal cancer treated with regorafenib, a prospective multicenter study
por: Lucidarme, Olivier, et al.
Publicado: (2019)

Evaluating radiological response in pancreatic neuroendocrine tumours treated with sunitinib: comparison of Choi versus RECIST criteria (CRIPNET_ GETNE1504 study)
por: Solis-Hernandez, Mª Pilar, et al.
Publicado: (2019)

Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib
por: van der Veldt, A A M, et al.
Publicado: (2010)

Modified response evaluation criteria in solid tumors is superior to response evaluation criteria in solid tumors for assessment of responses to sorafenib in patients with advanced hepatocellular carcinoma
por: Takada, Juichi, et al.
Publicado: (2015)

Early evaluation of sunitinib for the treatment of advanced gastroenteropancreatic neuroendocrine neoplasms via CT imaging: RECIST 1.1 or Choi Criteria?
por: Luo, Yanji, et al.
Publicado: (2017)

Necrosis volume and Choi criteria predict the response to endoscopic ultrasonography-guided HybridTherm ablation of locally advanced pancreatic cancer
por: Testoni, Sabrina Gloria Giulia, et al.
Publicado: (2020)

Comparison of the Diagnostic Performance of Response Evaluation Criteria in Solid Tumor 1.0 with Response Evaluation Criteria in Solid Tumor 1.1 on MRI in Advanced Breast Cancer Response Evaluation to Neoadjuvant Chemotherapy
por: Jeh, Su Kyung, et al.
Publicado: (2013)

Immune response evaluation criteria in solid tumors for assessment of atypical responses after immunotherapy
por: Ippolito, Davide, et al.
Publicado: (2021)

Evaluation of early imaging response criteria in glioblastoma multiforme
por: Gladwish, Adam, et al.
Publicado: (2011)

Evaluation of Proposed Criteria for Remission and Evidence‐Based Development of Criteria for Complete Response in Patients With Chronic Refractory Gout
por: Schlesinger, Naomi, et al.
Publicado: (2019)

A Phase Ib Study of Axitinib in Combination with Crizotinib in Patients with Metastatic Renal Cell Cancer or Other Advanced Solid Tumors
por: Michaelson, M. Dror, et al.
Publicado: (2019)

Agreement Between the European Organization for Research and Treatment of Cancer and Positron Emission Tomography Response Criteria in Solid Tumors in Evaluating Treatment Response in Solid Malignant Tumors
por: Nasir, Zafar, et al.
Publicado: (2019)

Gene Expression Analysis of Pak Choi in Response to Vernalization
por: Sun, Mengxia, et al.
Publicado: (2015)

Land evaluation criteria for irrigation
Publicado: (1979)

STatistically Assigned Response Criteria in Solid Tumors (STARCIST)
por: Bengtsson, Thomas, et al.
Publicado: (2015)

The Maze of Vasodilator Response Criteria
por: Douwes, J. Menno, et al.
Publicado: (2010)

Comparison of the 2022 ACR/EULAR Classification Criteria for Antineutrophil Cytoplasmic Antibody-Associated Vasculitis with Previous Criteria
por: Pyo, Jung Yoon, et al.
Publicado: (2023)

Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib
por: Kaneko, Shun, et al.
Publicado: (2020)

Evaluation of Response to Atezolizumab Plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma Using the Combination of Response Evaluation Criteria in Solid Tumors and Alpha-Fetoprotein
por: Kinami, Takahiro, et al.
Publicado: (2023)

S-Adenosyl-Methionine and Betaine Improve Early Virological Response in Chronic Hepatitis C Patients with Previous Nonresponse
por: Filipowicz, Magdalena, et al.
Publicado: (2010)

Computed Tomography Assessment of Hepatic Metastases of Breast Cancer with Revised Response Evaluation Criteria in Solid Tumors (RECIST) Criteria (Version 1.1): Inter-Observer Agreement
por: Ghobrial, Fady Emil Ibrahim, et al.
Publicado: (2017)

Design, Synthesis, and Biological Evaluation of Axitinib Derivatives
por: Wei, Na, et al.
Publicado: (2018)

Tumor response evaluation criteria for HCC (hepatocellular carcinoma) treated using TACE (transcatheter arterial chemoembolization): RECIST (response evaluation criteria in solid tumors) version 1.1 and mRECIST (modified RECIST): JIVROSG-0602
por: Sato, Yozo, et al.
Publicado: (2013)

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017)
por: Younes, A., et al.
Publicado: (2017)

Comparison of response evaluation criteria in solid tumors and tumor regression grade in evaluating the effect of preoperative systemic therapy of gastric cancer
por: Lai, Ming-Yu, et al.
Publicado: (2022)

Response Criteria for Intratumoral Immunotherapy in Solid Tumors: itRECIST
por: Goldmacher, Gregory V., et al.
Publicado: (2020)

Application of Fawcett’s Criteria in Theory Evaluation
por: Iduye, Steve
Publicado: (2022)

Preclinical models and evaluation criteria of prostatitis
por: He, Hailan, et al.
Publicado: (2023)

Angiogenic and immunomodulatory biomarkers in axitinib-treated patients with advanced renal cell carcinoma
por: Murphy, Danielle A, et al.
Publicado: (2020)

Circulating tumor DNA: Response Evaluation Criteria in Solid Tumors – can we RECIST? Focus on colorectal cancer
por: Spindler, Karen-Lise Garm, et al.
Publicado: (2023)

International criteria for measurement of tumour response
por: Ollivier, L., et al.
Publicado: (2015)

Axitinib versus sorafenib in advanced renal cell carcinoma: subanalyses by prior therapy from a randomised phase III trial
por: Escudier, B, et al.
Publicado: (2014)

Defining Clinical Response Criteria and Early Response Criteria for Precision Oncology: Current State-of-the-Art and Future Perspectives
por: Subbiah, Vivek, et al.
Publicado: (2017)

Comparison and evaluation of lupus nephritis response criteria in lupus activity indices and clinical trials
por: Corapi, Kristin M, et al.
Publicado: (2015)

A Conversation with Insung Choi
por: Bourzac, Katherine
Publicado: (2016)

The Operational Choi–Jamiołkowski Isomorphism
por: Adlam, Emily
Publicado: (2020)

Evaluation of the appropriateness of prescribing in geriatric patients using Beers criteria and Phadke's criteria and comparison thereof
por: Shah, Rima B., et al.
Publicado: (2011)

Analysis of Response Evaluation Criteria in Solid Tumors reduction ratio of primary chemotherapy in unresectable advanced or recurrent colorectal cancer
por: Kawagoe, Shiho, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_otjtd3n5mja6a4q3fla7issjnl